

Supplementary Table 1 Expert panel members, country and clinical role. * Working group chairs.

Name	Country	Clinical role	SPARC working group
Joe O'Sullivan	Ireland	Oncology	Biochemical Recurrence
Johannes Czernin	USA	Nuclear Medicine	Biochemical Recurrence
Daniela Oprea-Lager	Netherlands	Nuclear Medicine	Biochemical Recurrence
Tobias Maurer	Germany	Urology	Biochemical Recurrence
Matthias Eiber*	Germany	Nuclear Medicine	Biochemical Recurrence (co-lead & study steering group)
Anders Bjartell*	Sweden	Urology	Biochemical Recurrence (co-lead lead & study steering group)
Karolien Goffin	Belgium	Nuclear Medicine	Detection
Stephen Rowe	USA	Nuclear Medicine	Detection
Olivier Rouvière	France	Radiology	Detection
Louise Emmett*	Australia	Nuclear Medicine	Detection (co-lead lead & study steering group)
Jochen Walz*	France	Urology	Detection (co-lead lead & study steering group)
Declan Murphy	Australia	Nuclear Medicine	Primary staging
Clare Tempany	USA	Radiology	Primary staging
Piet Ost	Belgium	Radiation Oncology	Primary staging
Thomas Hope	USA	Nuclear Medicine	Primary staging
Philip Cornford	Ireland	Urology	Primary staging
Michael Hofman	Australia	Nuclear Medicine	Primary staging (co-lead lead & study steering group)
Alicia Morgans*	USA	Oncology	Primary staging (co-lead lead & study steering group)
Shahneen Sandhu	Australia	Oncology	Standardised reporting
Silke Gillissen	Switzerland	Oncology	Standardised reporting
Andrei Gafita	USA	Nuclear Medicine	Standardised reporting
Alberto Briganti	Italy	Urology	Standardised reporting
Stefano Fanti*	Italy	Nuclear Medicine	Standardised reporting (co-lead lead & study steering group)
Wolfgang Fendler*	Germany	Nuclear Medicine	Standardised reporting (co-lead lead & study steering group)
Karim Fizazi	France	Oncology	Treatment response
Oliver Sartor	USA	Oncology	Treatment response

Boris Hadaschik	Germany	Urology	Treatment response
Mike Sathekge	South Africa	Nuclear Medicine	Treatment response
Michael Morris*	USA	Oncology	Treatment response (co-lead lead & study steering group)
Ken Herrmann*	Germany	Nuclear Medicine	Treatment response (co-lead lead & study steering group)